Literature DB >> 3890911

Audit of a monitoring service for free phenytoin.

G M Peterson, S McLean, R J von Witt, K S Millingen.   

Abstract

This study assessed the value of introducing the measurement of free phenytoin levels in a public hospital. After publicising the availability and purpose of the assay, free phenytoin levels were determined either (a) on the doctor's request or (b) when the total level was requested and the patient's record showed evidence of factors predisposing to an elevated unbound fraction. Total phenytoin was measured by EMIT, and the unbound fraction by ultrafiltration at 37 degrees C using [14C]-phenytoin as a tracer. During a 9 month period, 70 free level determinations were performed on 46 patients. These comprised 20% of all phenytoin assays. The median free phenytoin fraction was 13.6% (range 9.3-28.6%). While total phenytoin levels were below the normal optimum range in 61% cases, free levels were probably therapeutic or above in 70% cases. Dosage adjustments were recommended on the basis of the free level, and were followed more often when the doctor had requested the free level assay (P less than 0.05). The results suggest that a free phenytoin level assay can improve the usefulness of therapeutic drug monitoring, particularly when the doctor understands the purpose of the assay.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3890911      PMCID: PMC1463837          DOI: 10.1111/j.1365-2125.1985.tb02697.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Rationale for monitoring free drug levels.

Authors:  R H Levy; T A Moreland
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

2.  Variability of phenytoin protein binding in epileptic patients.

Authors:  H J DeMonaco; L M Lawless
Journal:  Arch Neurol       Date:  1983-08

3.  Plasma protein binding of phenytoin in 100 epileptic patients.

Authors:  G M Peterson; S McLean; S Aldous; R J Von Witt; K S Millingen
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

4.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults.

Authors:  A Yacobi; T Lampman; G Levy
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

6.  Should we routinely measure free plasma phenytoin concentration?

Authors:  E M Rimmer; D C Buss; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

7.  Plasma concentrations of unbound phenytoin in the management of epilepsy.

Authors:  C J Kilpatrick; S Wanwimolruk; L M Wing
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

8.  Interindividual differences of protein binding in man.

Authors:  H Walther; F P Meyer
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-10
  8 in total
  2 in total

1.  Hemodialysis effects on phenytoin pharmacokinetics.

Authors:  Sarah Bezzaoucha; Amine Merghoub; Caroline Lamarche; Vincent Pichette; Jean-Philippe Lafrance; Louis-Philippe Laurin; Michel Vallée; Robert Robitaille; Martine Leblanc; Robert Bell
Journal:  Eur J Clin Pharmacol       Date:  2014-01-04       Impact factor: 2.953

2.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.